|
Year to Mar 2025
12 months to Mar 31, 2025
|
Year to Mar 2024
12 months to Mar 31, 2024
|
Year to Mar 2023
12 months to Mar 31, 2023
|
Year to Mar 2022
12 months to Mar 31, 2022
|
Year to Mar 2021
12 months to Mar 31, 2021
|
|
|---|---|---|---|---|---|
| Expenses | |||||
| Research and development | |||||
| General and administrative expenses | |||||
| Loss from operations | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone | |||||
| Gain on settlement with Parexel – iOx CRO | |||||
| Loss on Registered Direct Offering | |||||
| Offering costs | |||||
| Impairment loss - iOx IPR&D | |||||
| Impairment loss - Tarus IPR&D | |||||
| Impairment loss - Goodwill | |||||
| Impairment loss - Stimunity | |||||
| Impairment loss - Saugatuck | |||||
| Commitment fee under Committed Purchase Agreement | |||||
| Share of loss in associate accounted for using equity method | |||||
| Gain on dissolution of investment in associate | |||||
| Gain from sale of investment in public company | |||||
| Foreign exchange transaction gain (loss) | |||||
| Depreciation expense | |||||
| Interest income | |||||
| Interest expense | |||||
| Loss before provision for income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Other comprehensive loss | |||||
| Net unrealized loss on investments | |||||
| Total comprehensive loss for year | |||||
| Net loss attributable to: | |||||
| Owners of the Company | |||||
| Non-controlling interest | |||||
| Comprehensive loss attributable to: | |||||
| Owners of the Company | |||||
| Non-controlling interest | |||||
| Loss per share | |||||
| Basic and diluted | |||||
| Loss per share, Basic | |||||
| Loss per share, Diluted | |||||
| Weighted average shares outstanding | |||||
| Basic and diluted | |||||
| Weighted average shares outstanding, Basic | |||||
| Weighted average shares outstanding, Diluted | |||||
Loading...